An interaction between polymorphisms in FXR1 and one of its regulators, glycogen synthase kinase 3β, predicts symptom severity in schizophrenia and bipolar disorder (Benedict et al., 2017; Rampino et al., 2021). Here, FXR1 is linked to schizophrenia.